NOT FOR RELEASE OR DISTRIBUTION IN THE USA, CANADA, AUSTRALIA OR JAPAN.

SHOP APOTHEKE EUROPE: Consolidated revenues grow by +53% to over EUR 191 m in the first nine months of 2017.

• Market position in Germany further expanded with 31% growth.
• International sales almost tripled to EUR 53 m.
• Further acceleration of growth is expected in the fourth quarter as a result of the planned takeover of Europa Apotheek.

Venlo/Cologne, 24 October 2017. SHOP APOTHEKE EUROPE N. V. again achieved strong growth in the first nine months of the financial year 2017 (01.01. - 30.09.). According to preliminary calculations, the Group increased revenues by +53% to more than EUR 191 m after EUR 125 m in the corresponding period of the previous year. Thus, SHOP APOTHEKE EUROPE is once again the fastest growing online pharmacy in Europe.

In the core market shown in the "Germany" segment, which generates the highest sales, SHOP APOTHEKE EUROPE increased its revenue by +31% to almost EUR 138 m (previous year: EUR 105 m) in the reporting period. In the "International" segment, which includes the European markets of France, Italy, Spain, Austria, Belgium and the Netherlands, the company nearly tripled its revenue to around EUR 53 m (9M/2016: EUR 18 m) during the reporting period. The "Germany Services" segment, which comprises webshop services, generated sales of EUR 0.6 m (9M/2016: EUR 1.2 m) after eliminations for intragroup services.

Against the background of the planned acquisition of Europa Apotheek, which is expected to be completed in November 2017, the Management Board anticipates a further acceleration of growth at Group level in the fourth quarter of 2017, with a forecast for the Group's sales growth - as already reported on 25 September 2017 - of between +55% and +65%, after +45% to +55% earlier. The forecast for the consolidated EBITDA margin before non-recurring transaction expenses remains unchanged at -2.0% to -3.0%.

SHOP APOTHEKE EUROPE will publish its final figures and the complete interim report on
13 November 2017.

 

ABOUT SHOP APOTHEKE EUROPE.
SHOP APOTHEKE EUROPE is Continental Europe's leading online OTC pharmacy with a portfolio that focuses on OTC medication and pharmacy-related beauty and care products (BPC). With the takeover of Europa Apotheek planned for November 2017, SHOP APOTHEKE EUROPE will significantly enhance its European market leadership with an expanded product range for the whole family. The combination will create the fastest growing integrated online pharmacy with pro forma sales of around EUR 318 m in 2016.

SHOP APOTHEKE EUROPE already operates online pharmacies in Germany, Austria, France, Belgium, Italy, Spain and The Netherlands. In Germany, the TÜV-certified shop-apotheke.com is the market leader in terms of traffic. SHOP APOTHEKE EUROPE delivers a broad range of more than 100,000 original products to nearly 2.4 m active customers (as of September 2017) quickly and at attractive prices. In addition, SHOP APOTHEKE EUROPE provides comprehensive and consistent pharmaceutical services.

SHOP APOTHEKE EUROPE generated sales of about EUR 191 m in the first nine months of 2017 and a growth of +53% compared to the same period last year. Headquartered in Venlo (the Netherlands), SHOP APOTHEKE EUROPE also has offices in Cologne, Düsseldorf and Tongeren, Belgium. The online pharmacy has been listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) since 13 October 2016.

 

MEDIA CONTACTS.

Trade and public media:
Sven Schirmer
Mobil: +49 152 28 50 63 61
E-Mail: presse@shop-apotheke.com

Financial media:
Thomas Schnorrenberg
Mobil: +49 151 46 53 13 17
E-Mail: presse@shop-apotheke.com

Investor Relations:
Dr. Ulrich Wandel
Telefone: +31 77 850 6117
E-Mail: ulrich.wandel@shop-apotheke.com

DISCLAIMER.

This publication is an advertisement.
This communication constitutes neither an offer to sell nor a solicitation to buy securities of Shop Apotheke Europe N.V. in any jurisdiction. This is not a securities prospectus. Any public offering will be made solely by means of, and on the basis of, a securities prospectus, which will include detailed information about Shop Apotheke Europe N.V. An investment decision regarding the securities of Shop Apotheke Europe N.V. should only be made on the basis of the securities prospectus. Any securities prospectus will be published promptly upon approval by the Autoriteit Financiële Markten (AFM) and posted on http://shop-apotheke-europe.com/de/investorrelations/.
This communication does not constitute or form part of an offer of securities for sale or solicitation of an offer to purchase securities in the United States, Canada, Australia, Japan or in any other jurisdiction in which such offer may be restricted. The securities referred to in this communication have not been, and will not be, registered under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States, except on the basis of an applicable exemption from registration or in a transaction not subject to registration under the Securities Act. There will be no public offering of securities in the United States or anywhere else.
In the United Kingdom, this communication is directed only at persons who: (i) are qualified investors within the meaning of the Financial Services and Markets Act 2000 (as amended) and any relevant implementing measures and/or (ii) are outside the United Kingdom or (iii) have professional experience in matters relating to investments and fall within the definition of "investment professionals" contained in article 19 (5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the "Order") or are persons falling within article 49 (2)(a) to (d) (high net worth companies, unincorporated associations, etc.) of the Order, or fall within another exemption to the Order (all such persons referred to in (i) to (iii) above together being referred to as "Relevant Persons"). Any person who is not a Relevant Person must not act or rely on this communication or any of its contents. Any investment or investment activity to which this communication relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.
Statements contained herein may constitute "forward-looking statements." Forward-looking statements are generally identifiable by the use of the words "may", "will", "should", "plan", "expect", "anticipate", "estimate," "believe", "intend", "project", "goal" or "target" or the negative of these words or other variations on these words or comparable terminology.
Forward-looking statements are based on current expectations and involve a number of known and unknown risks, uncertainties and other factors that could cause the Group's or its industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. You should not place undue reliance on forward-looking statements and the Group does not undertake publicly to update or revise any forward-looking statement that may be made herein, whether as a result of new information, future events or otherwise.